Evidence-based medicine can impose high self-care demands on patients with diabetes ([@B1]--[@B4]), negatively affecting adherence and quality of life ([@B5]--[@B7]). Little is known about how patient-experienced burden of treatment (BOT) ([@B8]--[@B10]) becomes articulated and addressed in routine clinical encounters, where patients' care needs are usually discussed ([@B11]--[@B13]). To understand these issues, we analyzed videos of primary care encounters between patients with type 2 diabetes and clinicians to assess the prevalence of BOT discussions, their characteristics, and their efficacy in generating efforts to reduce BOT.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Data {#s6}
----

The Mayo Clinic Institutional Review Board approved all procedures. Data consisted of videos of clinical visits obtained from both study arms of a randomized trial ([@B1]) of a decision aid to help choose antihyperglycemic agents (including insulin), versus usual care, among 85 adults with type 2 diabetes recruited from 11 primary care sites in Minnesota. Eligible patients had diabetes for at least 1 year, had poor glycemic control (HbA~1c~ ≥7.0), and were not on insulin. Videographic data are useful for assessing patient-clinician communication ([@B13],[@B14]); we reviewed all 46 available videos for which patients and clinicians gave written informed consent.

Analysis {#s7}
--------

We conducted quantitative content analysis ([@B15]--[@B19]). Analytic categories, derived a priori, were applied during coding, resembling the directed or summative approaches of Hsieh and Shannon ([@B20]). To reduce bias, two authors (K.B. and E.S.) coded each video.

On the basis of existing literature ([@B2],[@B8],[@B10]), we defined BOT as treatment-related effects that limit the patient's ability to participate in activities and tasks that are crucial to his or her quality of life and that are not attributable to underlying disease. We identified four analytic domains of BOT for coding via team discussion based on literature ([@B2],[@B8],[@B21]) and feedback from other experts: access, administration, effects, and monitoring (see [Table 1](#T1){ref-type="table"}).

###### 

Domains and characteristics of BOT discussions
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BOT discussions were considered addressed when they generated problem-solving efforts by clinicians and/or patients, including any statements regarding methods or strategies to alleviate BOT. No single solution had to be agreed on---only attempts at reducing BOT. Coders used a standard form to code videos and guide interrater comparisons. No limit was set on the number of BOT discussions coded per video.

To optimize interrater reliability, coders completed a training analysis of similar videos until they reached \>90% agreement. During this process, coders discussed ambiguous situations and developed classification rules to ensure consistency. Finally, both coders watched each video, sometimes multiple times, to identify and classify BOT discussions.

Statistical analyses were generally descriptive. Although sample size limited their usefulness, where possible, we used χ^2^ tests and two-sample tests of proportions (nominal significance *P* \< 0.05) using StataSE 11 (StataCorp, College Station, TX) to test associations between discussion characteristics.

RESULTS {#s8}
=======

A total of 19 patients were in the control arm (37% female, mean age 63.5, mean visit length 21.3 min), whereas 27 patients were in the decision aid arm (56% female, mean age 61.5, visit length 26.5 min).

Any BOT discussion {#s9}
------------------

Initial interrater agreement on presence of any BOT discussion was 85%. After consensus, coders found 43 videos to contain at least one discussion (16 control arm, 27 decision aid arm).

Number of discussions {#s10}
---------------------

Initially, 120 BOT discussions were identified. Coders independently identified 53 of the same discussions (3 were coded in different domains, requiring consensus). After reviewing the other 67 discussions, 30 were included through consensus by both coders (final total: 83 discussions).

Discussion characteristics {#s11}
--------------------------

Patients initiated 55% of BOT discussions ([Table 1](#T1){ref-type="table"}). Discussion initiator and trial arm allocation were significantly associated with domain (*P* = 0.035 and *P* = 0.031, respectively). Only 30% of discussions were unambiguously addressed.

CONCLUSIONS {#s12}
===========

Our results have limitations. Although well suited to descriptively studying discussions, sample size prevented further exploration and meaningful statistical tests. Despite coder training, some discussions remained difficult to code, and consensus may not fully prevent categorization errors. Work is needed to further develop and validate BOT domains; rater bias may interact with lack of clarity about what constitutes BOT owing to sparse literature on the subject.

At the time of the study, no validated BOT tools existed. Domains were constructed a priori, but criteria evolved during the training period. Current shortcomings in knowledge of BOT, including poor understandings of patients' experiences, could be overcome via validated measures and qualitative inquiry.

Because participants knew they were being video recorded (and may have felt compelled to speak more), BOT discussions may have been overstated. Although decision aids elicited more discussions than usual care, this may reflect greater visit length in this arm or a higher proportion of women (as gendered interaction patterns may affect discussions). Design also may inject bias via trial eligibility (insulin users---excluded here---may differ in articulations of BOT) and video consent (consenters may be less burdened or more responsive, although measured characteristics showed little difference) ([@B1]). Also, we examined discussions within one visit; some may have been addressed at subsequent visits to which we have no access. Thus, results deserve caution.

Despite limitations, the data offer important strengths and contributions. Rather than surveys or other data removed from clinical encounters, this study incorporated direct observation of real primary care visits. Discussions were recorded in real time (negating the need for retrospection), and participants were unaware of the purpose of this substudy during visits.

Few studies address patients' articulations of BOT and/or clinician responses. Our findings partially echo a previous study, which finds that clinicians target biomedical problems more than sociobehavioral factors, such as access or social support ([@B22]). However, here, access was prevalently addressed; administration and monitoring, suggesting patients' concerns about day-to-day self-care demands, were relatively unaddressed. In that previous study, concealed actors ensured standardized scenarios. By contrast, we studied uncontrolled encounters and so were able to explore how BOT---a patient-experienced phenomenon---does or does not become articulated within clinical visits for diabetes.

Patients with diabetes routinely discuss BOT with clinicians but often with no effect. In the context of diabetes and other chronic diseases, this represents lost opportunities to offset preventable nonadherence, costs, and poorer quality of life for patients. As we progress toward providing minimally disruptive medicine, clinicians may need education on strategies for discussing and addressing BOT with patients.
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